Harrow, Inc. Long-Term Debt, Maturity, Year Five
Harrow, Inc. (HROW) had Long-Term Debt, Maturity, Year Five of $250.00 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2026-03-02
- 2025-12-31: Long-Term Debt, Maturity, Year Five $250.00M.
- 2022-12-31: Long-Term Debt, Maturity, Year Five $39.16M.
- 2021-12-31: Long-Term Debt, Maturity, Year Five $77.16M.
- 2021-09-30: Long-Term Debt, Maturity, Year Five $77.16M.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2025-12-31 | $250.00M 10-K · filed 2026-03-02 |
| 2022-12-31 | $39.16M 10-K · filed 2023-03-23 |
| 2021-12-31 | $77.16M 10-K · filed 2022-03-10 |
| 2021-09-30 | $77.16M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $77.16M 10-Q · filed 2021-08-10 |
| 2017-12-31 | $11.20M 10-K · filed 2018-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |